Media

Pretzel Therapeutics Presents Preclinical Data on PX578 at MDA 2026, Further Supporting Clinical Advancement in Individuals Living with POLG Disease

Spruce Biosciences Appoints Dale Hooks, an Accomplished Rare Disease Commercial Leader, as Chief Commercial Officer

Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates

Oncopeptides secures fast-track designation for Window-of-Opportunity study in glioblastoma

Intervacc presents to the capital market on three occasions in March

Vicore Pharma to Present at Upcoming Investor Conferences

Hemab Therapeutics Receives FDA Breakthrough Therapy Designation for Sutacimig in Glanzmann Thrombasthenia

Oncorena receives regulatory approval in France and Portugal to initiate the Oncorella-1 clinical study

Kivu Bioscience Appoints Brunilda Shtylla as Chief Business Officer

Vicore Pharma to Present at Upcoming Investor Conferences